Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial

Ali Jalali, Danielle A. Ryan, Philip J. Jeng, Kathryn E. McCollister, Jared A. Leff, Joshua D. Lee, Edward V. Nunes, Patricia Novo, John Rotrosen, Bruce R. Schackman, Sean M. Murphy

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To examine the health-related quality-of-life (HRQoL) of persons with opioid use disorder (OUD) seeking treatment in an inpatient detoxification or short-term residential setting; continuing treatment as outpatients. Methods: We conducted a secondary analysis of data from a clinical trial (N = 508) where participants were randomized to extended-release naltrexone or buprenorphine-naloxone for the prevention of opioid relapse. We used a generalized structural equation regression mixture model to identify associations of HRQoL (EQ-5D) trajectories, including latent characteristics, over the 24-week trial and 36-week follow-up period, among participants who reported HRQoL beyond baseline. This novel framework accounted for baseline and time-varying characteristics, while simultaneously identifying latent classes. Results: We identified two subpopulations: HRQoL “pharmacotherapy responsive” (82.3 %) and HRQoL “characteristic sensitive” (17.7 %). The pharmacotherapy responsive subpopulation was characterized by a shortterm HRQoL improvement and then stable HRQoL over time, and by a positive association between HRQoL and receiving pharmacotherapy in the past 30 days. The characteristic sensitive subpopulation was characterized by an initial improvement in HRQoL with a gradual decline over time, and no significant HRQoL response to pharmacotherapy. HRQoL changes over time in this subpopulation were more influenced by baseline demographic, socioeconomic, and psychosocial characteristics. Conclusion: Our findings suggest that while HRQoL may be improved and sustained through targeted efforts to promote use of pharmacotherapy for many persons with OUD, an identifiable subpopulation may require additional services that address socioeconomic and psychosocial issues to achieve HRQoL benefits. Our analysis provides insight for improving individualized care for persons with opioid use disorder seeking treatment.

Original languageEnglish (US)
Article number108221
JournalDrug and alcohol dependence
Volume215
DOIs
StatePublished - Oct 1 2020

Keywords

  • Health-related quality-of-life
  • Latent class analysis
  • Medications for opioid use disorder
  • Opioid use disorder
  • Regression mixture modeling

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial'. Together they form a unique fingerprint.

Cite this